Neurocrine Biosciences (NBIX) Property, Plant & Equipment (Net) Growth (3y) (2013 - 2026)
Neurocrine Biosciences (NBIX) Property, Plant & Equipment (Net) Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PP&E (Net) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.92 Bn | 42.96 Bn | - | 5.84% |
| 2 | Teva Pharmaceutical Industries | 43.19 Bn | 39.53 Bn | 2.15 Bn | -11.73% |
| 3 | Zoetis | 31.74 Bn | 30.06 Bn | 1.05 Bn | 7.65% |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.87 Bn | 5.10 Bn | 0.86% |
| 5 | United Therapeutics | 22.22 Bn | 19.56 Bn | 683.80 Mn | 27.15% |
| 6 | Viatris | 18.71 Bn | 17.83 Bn | 1.46 Bn | -6.48% |
| 7 | Neurocrine Biosciences | 15.55 Bn | 15.16 Bn | 935.80 Mn | 11.32% |
| 8 | Elanco Animal Health | 11.80 Bn | 11.27 Bn | 798.00 Mn | 11.90% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | 28.35% |
| 10 | Alkermes | 8.12 Bn | 7.47 Bn | 397.90 Mn | -12.32% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.32% |
| Mar 31, 2026 | 13.12% |
| Dec 31, 2025 | 15.29% |
| Sep 30, 2025 | 16.90% |
| Jun 30, 2025 | 11.14% |
| Mar 31, 2025 | 10.83% |
| Dec 31, 2024 | 12.12% |
| Sep 30, 2024 | 16.12% |
| Jun 30, 2024 | 17.01% |
| Mar 31, 2024 | 18.46% |
| Dec 31, 2023 | 16.65% |
| Sep 30, 2023 | 16.96% |
| Jun 30, 2023 | 13.73% |
| Mar 31, 2023 | 14.44% |
| Dec 31, 2022 | 11.83% |
| Sep 30, 2022 | 14.75% |
| Jun 30, 2022 | 19.02% |
| Mar 31, 2022 | 20.35% |
| Dec 31, 2021 | 20.05% |
| Sep 30, 2021 | 21.32% |